Pfizer has teamed up with Blackstone to secure up to $1.5 billion in funding for berobenatide, a potential first-in-class monthly GLP-1 agonist aimed at treating obesity. This move is critical as Pfizer faces stagnant revenues, heavy debt, and upcoming patent expiries on key drugs. Berobenatide offers advantages like monthly dosing and potentially lower manufacturing costs, but it still has significant gaps in safety and efficacy data compared to established competitors. Despite Blackstone's financial backing, investor confidence in Pfizer's GLP-1 prospects remains cautious due to execution risks.
Pfizer's partnership with Blackstone to fund berobenatide highlights ongoing challenges in the obesity drug market. On Pluang, Pfizer's stock trades at USD 28.88, down 1.94% as of Nov 13, 2026 05:21 WIB, with a market cap of $167.86 billion. Despite cautious investor sentiment, the stock sees a strong buy interest with 72% of orders on Pluang being purchases, reflecting active engagement in the health sector.
DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments includi...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
